MattsonJack Debuts Chinese Oncology Measure

Pharma and biotech specialist MattsonJack has launched a study that focuses on specific cancer tumor types in China.

'CancerMPact Treatment Architecture China 2009' includes in-depth analysis of treatment and drug utilization, and provides an assessment of current clinical management of cancer by state.

It also compares treatment across China, the US and Japan through primary research combined with secondary data. In-depth, in-person, native-language interviews are conducted with treating physicians for each tumor type, and the results are combined with academic clinical research.

'Access to healthcare in China has improved significantly over the last two decades,' says SVP Ian Hicks. 'It is imperative for companies to understand the demographics, lifestyle shift, and current standards of care - which differ significantly from those in the G7 countries - to support strategic decisions in China's dynamic and emerging oncology care market.'

Formed in 1986, MattsonJack is now part of the Kantar group. Last September, the firm introduced CancerNFluence - an online database of peer-nominated physicians who influence cancer treatment decisions.

Web site: www.mattsonjack.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Mattson Jack Group (MJG)
• All news